Loading candles…
Marksans Pharma operates in the pharmaceutical industry focusing on the formulation of pharmaceutical products, primarily generic drugs. The company encompasses activities across the pharmaceutical value chain including research and development, manufacturing, and global marketing. It serves markets in the United Kingdom, United States, Australia, and Europe. Marksans Pharma's business segments include Research and Development (R&D), Manufacturing, Global Marketing, the Over-the-Counter (OTC) segment, and the Prescription (Rx) market. The OTC pharmaceutical segment accounts for the majority of the company's revenue. No information on founders, key management, incorporation details, subsidiaries, or stock listings is provided.
This page is a live market overview for MARKSANS PHARMA LIMITED (MARKSANS) on the NSE. As a listed security, MARKSANS PHARMA LIMITED is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for MARKSANS before placing trades on tick2trade.
As of the latest feed, MARKSANS last traded at ₹273.85 on NSE, up ₹4.95 (1.84%) from the previous close of ₹268.9. Today's session range is ₹267.25 – ₹275.4, against a 52-week band of ₹155 – ₹281.6. Traded volume today stands at 10.12L shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for MARKSANS in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether MARKSANS is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for MARKSANS PHARMA LIMITED before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in MARKSANS. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated MARKSANS option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Unaudited Results - Q1-FY26 | To consider and approve the Unaudited Financial Results for the quarter ended Jun 30, 2026 | 12 Aug 2026 |
| Audited Results - FY26 | To consider and approve Audited Standalone and Consolidated Financial Results and to consider recommendation of dividend if any, for the Financial Year ended… | 26 May 2026 |
| Results - Q3-FY25 | To consider and approve the financial results for the quarter ended December 31, 2025 | 5 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 13 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 12 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and dividend | 19 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.